PierianDx company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.


Founded Year



Series B - II | Alive

Total Raised


Last Raised

$30M | 9 mos ago

About PierianDx

PierianDx provides genomic software and services to enable data-driven personalized medicine. The company's genomics software platform, Clinical Genomicist Workstation (CGW), provides data-driven workflow for health systems, academic medical centers, and commercial labs to improve patient outcomes through precise genomic analysis, interpretation, and reporting.

PierianDx Headquarter Location

6 Cityplace Dr. Suite 550

Creve Coeur, Missouri, 63141,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing PierianDx

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned PierianDx in 2 CB Insights research briefs, most recently on Feb 15, 2022.

Expert Collections containing PierianDx

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

PierianDx is included in 5 Expert Collections, including Conference Exhibitors.


Conference Exhibitors

5,302 items



1,267 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data


Digital Health

13,084 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)


Biopharma Tech

260 items


Precision Medicine Tech Market Map

160 items

This CB Insights Tech Market Map highlights 160 precision medicine companies that are addressing 9 distinct technology priorities that pharmaceutical companies and healthcare providers face.

Latest PierianDx News

Next-generation Sequencing Market Size to Hit US$ 24.48 Bn by 2030

Jan 20, 2022

Companies Covered BGI Group, PierianDx Inc., F. Hoffmann-La Roche AG, Pacific Biosciences of California Inc., PerkinElmer Inc., Thermo Fisher Scientific Inc., Agilent Technologies Inc., Illumina Inc., Qiagen N.V., Precigen Inc. Report Highlights Based on the product, the consumables segment dominated the global next-generation sequencing market in 2020 with highest market share. The consumables have a short lifespan, resulting in a high replacement rate, which drives increasing demand for them. The consumables are also ordered in large quantities from many manufacturers because it has been demonstrated to be cost-effective method for researchers and scientists to increase market value. Based on the application, the biomarker and cancer segment dominated the global next-generation sequencing market in 2020 with highest market share. Due to an increase in the occurrence of different kind of cancers, the global next-generation sequencing market is predicted to develop significantly during the forecast period. Ask here for more customization study@ https://www.precedenceresearch.com/customization/1454 Market Dynamics Drivers - Rising research and development activities The increasing research and development activities for developing therapies used in the treatment of genetic disorders will increase the demand for next generation sequencing methods over the course of the study. Increased investments in research and development activities, as well as an increase in the number of studies on the treatment of genetic disorders in individuals, will create a massive market demand. Governments in developed economies have implemented a number of policies and enacted legislation to encourage scientists and researchers to find solutions to chronic and rare diseases. Thus, the rising research and development activities are driving the growth of next-generation sequencing (NGS) market. Restraints - Lack of clinical validation Due to a lack of scientific evidence, the clinical validity of direct-to-consumer genetic tests has been consistently questioned. This has an adverse effect on the commercialization of predisposition tests. Single-gene testing by Sanger sequencing is used in direct-to-consumer tests because it is the most cost-effective method for studying inherited disorders with low phenotypic and genetic heterogeneity. With the increase in heterogeneity, it is more efficient to use next-generation sequencing (NGS) panels to study multiple targets at the same time. Furthermore, direct-to-consumer genetic tests have limited accuracy and frequently produce false-positive or false-negative results, which can have a negative impact on consumer health and cause emotional and mental distress. This has compelled regulatory authorities to scrutinize vendors and mandate the disclosure of risk information and instructions. Opportunities - Advancement in next-generation sequencing (NGS) platforms The continuous technological advancements in sequencers have enabled the introduction of efficient, portable, and simple-to-use of next-generation sequencing (NGS) platforms capable of providing rapid and accurate results and boasting improved turnaround times. The launch of next-generation sequencing (NGS) technologies provides key market players with a benefit; as a result, the market companies are highly investing on research and development of new technologies to drive the market growth. As a result, the advancement in of next-generation sequencing (NGS) platforms is creating lucrative opportunities for the growth of the market. Challenges - End user budget constraints In developing countries, the academic research is mostly reliant on outside financing. Despite private and government sector attempts to offer funding for research around the world, numerous research and academic institutes have budget limits when it comes to the purchase and use of innovative and high-priced equipment and technology. As a result, advanced research facilities in academic and research institutes in underdeveloped countries are being installed at a slow pace. Thus, end user budget is a big challenge for the market growth. Browse more Healthcare Industry Research Reports@ https://www.precedenceresearch.com/industry/healthcare Segments Covered in the Report By Product Others Buy this Premium Research Report@  https://www.precedenceresearch.com/checkout/1454 You can place an order or ask any questions, please feel free to contact at  sales@precedenceresearch.com  | +1 9197 992 333 About Us Precedence Research is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Precedence Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings. We are obliged to serve our different client base present over the enterprises of medicinal services, healthcare, innovation, next-gen technologies, semi-conductors, chemicals, automotive, and aerospace & defense, among different ventures present globally. For Latest Update Follow Us:

PierianDx Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

PierianDx Rank

  • When was PierianDx founded?

    PierianDx was founded in 2014.

  • Where is PierianDx's headquarters?

    PierianDx's headquarters is located at 6 Cityplace Dr., Creve Coeur.

  • What is PierianDx's latest funding round?

    PierianDx's latest funding round is Series B - II.

  • How much did PierianDx raise?

    PierianDx raised a total of $88.3M.

  • Who are the investors of PierianDx?

    Investors of PierianDx include Inova Health Systems, Health Catalyst Capital Management, ATW Partners, SJF Ventures, OrbiMed Advisors and 7 more.

  • Who are PierianDx's competitors?

    Competitors of PierianDx include Q-State Biosciences.

You May Also Like

Navican Genomics

Navican provides a personalized approach to testing, diagnosing, and treating cancer. The company's unique process analyzes the genetic makeup of a patient's cancer and employs a team of skilled molecular tumor specialists to review each test and determine how to most effectively treat that cancer case.

Tempus Logo

Tempus builds a library of molecular and clinical data as well as a corresponding operating system for data accessibility and use. The company enables physicians to deliver personalized cancer care for patients through its interactive analytical and machine learning platform. It provides genomic sequencing services and molecular and therapeutic data analysis to empower physicians to make real-time, data-driven decisions.

Fabric Genomics Logo
Fabric Genomics

Fabric Genomics, formerly Omicia, is a computational genomics company offering end-to-end genomic data analysis, annotation, curation, classification and reporting solutions to clinical labs, hospital labs, country sequencing programs and life science companies. Fabric Genomics' analytic capabilities begin with raw data analysis and include the delivery of rapid, comprehensive insights for high throughout panels, exomes, and whole genomes. The company can process any NGS file input (e.g. FASTQ, BAM or VCF) providing alignment, variant calling, annotation, guideline-driven variant classification, variant interpretation and clinical reporting for both hereditary disease and oncology. Fabric Genomics was founded by scientists and industry pioneers in bioinformatics, large-scale genomics and molecular diagnostics, and is headquartered in Oakland, California with satellite offices in London, Seattle, Salt Lake City and Boston. By accelerating access to insights related to the cause of genetic diseases, Fabric Genomics is leading the way in precision healthcare.

Gene42 Logo

Gene42 is a medical technology and clinical software company that develops clinical software tools for collecting and analyzing phenotypic information for patients with genetic disorders and cancers. Their solution, PhenoTips, allows for efficient recording of patient data in a standardized format, which facilitates automated searches of annotated genes and disease databases (differential diagnosis), enables effortless querying and sharing of anonymized patient data by users and provides a user-friendly interface with advanced features that reduces clinician's workload and seamlessly integrates into clinical work flow. Gene42 provides support contracts and custom development for PhenoTips software. Data organization when it comes to patient care is critical, especially in rare diseases when certain symptoms or features of a disease might not be seen on a regular basis. In the age of "big data" and electronic health records, Gene42 is striving to make personalized medicine more effective for patients and their doctors.

Q-State Biosciences

Q-State Biosciences is a precision medicine company creating new genetically targeted medicines for people living with nervous system disorders. The company's proprietary ResQueTM Platform incorporates a suite of technologies to map each patient’s unique genome to a genetic therapy that targets the root cause of disease.

Illumina Logo

Illumina works to apply new technologies and revolutionary assays to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. These studies will help make the realization of personalized medicine possible. With such rapid advances in technology taking place, it is mission critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers. Illumina's innovative, array-based solutions for DNA, RNA, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic. The company was founded in 1998 and is based in San Diego, California.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.